Skip to Main Content

Leukemia and Lymphoma Clinical Trials

Open clinical trials for leukemia and lymphoma

Recruiting
AML23: Venetoclax and Conventional Chemotherapy for Acute Myeloid Leukemia

Full title:

A Collaborative Phase 2 Study of Venetoclax in Combination with Conventional Chemotherapy in Pediatric Patients with Acute Myeloid Leukemia

Study goal:

Study the side effects of using venetoclax and chemotherapy to treat children with AML; learn more about how this treatment works

Age:

Older than 28 days and younger than 22 years

Recruiting
APAL2020D: Venetoclax in Children with Relapsed Acute Myeloid Leukemia

Full title:

A Randomized Phase 3 Trial of Fludarabine/ Cytarabine/ Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML

Study goal:

To find out if adding venetoclax to standard chemotherapy leads to improved survival for children and young adults with relapsed AML.

Age:

29 days old to 21 years old

Recruiting
CATCHAML: CAR T-Cell Therapy for Acute Myelogenous Leukemia (AML)

Full title:

CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Study goal:

The main purpose of this study is to find the highest dose of CD123-CAR T cells that is safe to give patients with AML.  We also want to study the side effects of the treatment and learn how effective it is in fighting this type of cancer.

Age:

21 years old or younger

Recruiting
CPXSMN: CPX-351 in Pediatric Patients with Secondary Myeloid Neoplasms

Full title:

A Prospective, Multicenter, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years with Secondary Myeloid Neoplasms 

Study goal:

This study will help us understand the effects of CPX-351 treatment in patients with MDS and AML.

Age:

1-22 years old

Recruiting
DIRECT70: CAR T–Cell Therapy for Children with Blood Malignancies

Full title:

CAR T–Cell Therapy Directed to CD70 for Pediatric Patients with Hematological Malignancies (DIRECT70)

Study goal:

The purpose of this study is to find the highest dose of CD70+ CAR cells that is safe to give to patients with CD70+ blood cancers.

Diagnosis:

ALL, AML, MDS, Lymphoma

Age:

Up to 21 years old

Recruiting
Published results
G4K: Genomes for Kids

Study goal:

The main goal of this study is to learn more about the reasons childhood tumors form and how to treat them better.

Recruiting
HODNIRS: Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors

Full title:

Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors

Study goal:

Understand the relationship among cardiopulmonary function, carotid sinus baroreceptors and CO2 sensing organs, and cerebral blood flow regulation in Hodgkin lymphoma survivors

Diagnosis:

Hodgkin lymphoma

Age:

Age 18 and up

Clinical trial categories:

Lymphoma Hodgkin Lymphoma
Recruiting
INOMRD: Inotuzumab Ozogamicin for High-Risk B-Cell Acute Lymphoblastic Leukemia

Full title:

Inotuzumab Ozogamicin for Children with MRD Positive CD22+ Acute Lymphoblastic Leukemia

Study goal:

The main goal of this study is to learn about the good and bad side effects of inotuzumab ozogamicin in children with this type of leukemia and to find out how well the drug works to get rid of the disease.

Age:

Younger than 22 years old

Recruiting
MEMCAR19: Allogeneic CAR T-Cell Therapy for Relapsed/Refractory CD19-Positive Leukemia

Full title:

A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia

Study goal:

The main goal of this study is to learn the largest dose of memory CAR T cells that can be safely given. Researchers also want to learn about the way memory CAR T cells act in the body and how effectively they treat this type of cancer.

Age:

Donor: At least 19 years old; Recipient: 21 years or younger

Recruiting
NCBP01: Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation

Full title:

A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

Study goal:

The primary purpose of this study is to examine the safety of administration of the unlicensed investigational NCBP HPC-CORD BLOOD products in a multi-institution setting.

Diagnosis:

Leukemia and other blood diseases

Recruiting
PAINBDY1: Treating Pain in Children with Cancer: Pain Buddy

Full title:

Mobile Technology to Improve Pain and Symptoms in Children With Cancer

Study goal:

The main goal of this research study is to help us learn how to better treat pain and symptoms in children going through chemotherapy cancer treatment.

Age:

8 to 18 years old

Recruiting
PEPN2011: Tegavivint Treatment for Solid Tumors, Lymphomas, and Desmoid Tumors

Full title:

A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Study goal:

The main purpose of this study is to find out how well the medicine tegavivint works to help children, teens, and young adults with certain recurrent or refractory solid tumors.

Age:

12 months to 30 years

Recruiting
PEPN2111: Phase 1/2 Trial of CBL0137 for Relapsed or Refractory Solid Tumors and Lymphoma

Full title:

A Phase 1/2 Trial of CBL0137 in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma

Study goal:

The main purpose of this study is to find the highest, safest dose of CBL0137 that can be given to children, teens and young adults with solid tumors or lymphoma.

Age:

12 months to 21 years old with diagnosis of relapsed or refractory solid tumor or lymphoma (including CNS tumors) or progressive or recurrent DIPG or other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy; 12 months to 30 years old with diagnosis of relapsed or refractory osteosarcoma

Recruiting
RAVAML: Revumenib, Azacitidine, and Venetoclax for Pediatric AML

Full title:

A Phase 1 Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients with Refractory or Relapsed Acute Myeloid Leukemia

Study goal:

Find out the dose of revumenib, azacitidine and venetoclax that can be used to safely treat children, adolescents, and young adults with refractory or relapsed AML or ALAL

Diagnosis:

Acute myeloid leukemia or acute leukemia of ambiguous lineage

Age:

1–30 years old

Recruiting
REF2HCT: Haploidentical Bone Marrow Transplant for Relapsed or Refractory Leukemia, Lymphoma, or Myelodysplastic Syndrome After an Earlier Transplant

Full title:

Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation

Study goal:

The main goal of this study is to learn about the good and bad effects of transplanting blood cells donated by a family member to children and young adults with cancer that has come back or did not improve after a previous bone marrow transplant.

Diagnosis:

Leukemia, Lymphoma, Myeloid sarcoma, Myelodysplastic syndrome, Juvenile Myelomonocytic Leukemia, Non-Hodgkin Lymphoma

Age:

21 years old and younger

Recruiting
SELCLAX: A Study of Venetoclax and Selinexor with Chemotherapy in Children with AML

Full title:

A Phase I and Expansion Cohort Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Study goal:

The main goals of this study are to test the safety of venetoclax and selinexor and find the highest dose that is safe to give when combined with chemotherapy drugs. Researchers also want to find out about any side effects and learn how the treatment affects your body.

Age:

30 years or younger

Recruiting
SJLIFE: Establishment of a Lifetime Cohort of Adults Surviving Childhood Cancer

Full title:

SJLIFE: Establishment of a Lifetime Cohort of Adults Surviving Childhood Cancer

Study goal:

To establish a lifetime group of childhood cancer survivors treated at St. Jude Children’s Research Hospital and to evaluate health outcomes in aging survivors of pediatric cancer

Age:

Participants must be at least 5 years from diagnosis of childhood cancer between 1962-2012, treated and followed at St. Jude

Clinical trial categories:

Childhood Cancer Brain Tumors Leukemia Solid Tumors
Recruiting
SJLTFU: Protocol for Collecting Data on Childhood Cancer Survivors

Full title:

SJLTFU: Protocol for Collecting Data on Childhood Cancer Survivors

Study goal:

To collect information about the effects of childhood cancer and its treatment on the patients who are treated or followed after treatment for childhood cancer at St. Jude Children’s Research Hospital

Clinical trial categories:

Childhood Cancer Brain Tumors Leukemia Solid Tumors
Recruiting
SJPROTON2: Effects of Patient Positioning on Accuracy of Pediatric Proton Therapy

Full title:

Estimating Setup Uncertainty in Pediatric Proton Therapy Using Volumetric Images

Study goal:

The main goal of this study is to collect information about how a patient is positioned and set up for radiation therapy.

Clinical trial categories:

Childhood Cancer Brain Tumors Lymphoma Solid Tumors
Recruiting
TRIALS: Transfusional Iron Overload Among Leukemia Survivors

Full title:

TRIALS: Transfusional Iron Overload Among Leukemia Survivors

Study goal:

1) To find out how many long-term survivors of leukemia have iron overload by using MRI testing. 2) To study how the number of red blood cell transfusions you received determines whether you have iron overload. 3) To explore how your age at the time of cancer therapy, the length of time from therapy, and gender affects whether you develop iron overload. 4) To find out if iron overload is causing problems with your organs.

Diagnosis:

Leukemia Survivors

Recruiting
cHOD17: Risk-Adapted Therapy for Children and Young Adults with Hodgkin Lymphoma

Full title:

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Study goal:

The main goal of this study is to see if this approach can reduce treatment-related late effects in children and young adults with Hodgkin lymphoma.

Diagnosis:

Hodgkin Lymphoma

Age:

21 years or younger (low-risk patients)
25 years or younger (high-risk patients)

Clinical trial categories:

Childhood Cancer Hodgkin Lymphoma Lymphoma